Structure, anti-SARS-CoV-2, and anticoagulant effects of two sulfated galactans from the red alga Botryocladia occidentalis.
Anti-SARS-CoV-2
Anticoagulation
Botryocladia occidentalis
Structural determination
Sulfated galactan
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
29
01
2023
revised:
13
03
2023
accepted:
21
03
2023
pmc-release:
31
05
2024
medline:
15
5
2023
pubmed:
25
3
2023
entrez:
24
3
2023
Statut:
ppublish
Résumé
The structure of the sulfated galactan from the red alga Botryocladia occidentalis (BoSG) was originally proposed as a simple repeating disaccharide of alternating 4-linked α-galactopyranose (Galp) and 3-linked β-Galp units with variable sulfation pattern. Abundance was estimated only for the α-Galp units: one-third of 2,3-disulfation and one-third of 2-monosulfation. Here, we isolated again the same BoSG fractions from the anion-exchange chromatography, obtaining the same NMR profile of the first report. More careful NMR analysis led us to revise the structure. A more complex sulfation pattern was noted along with the occurrence of 4-linked α-3,6-anhydro-Galp (AnGalp) units. Interestingly, the more sulfated BoSG fraction showed slightly reduced in vitro anti-SARS-CoV-2 activities against both wild-type and delta variants, and significantly reduced anticoagulant activity. The BoSG fractions showed no cytotoxic effects. The reduction in both bioactivities is attributed to the presence of the AnGalp unit. Docking scores from computational simulations using BoSG disaccharide constructs on wild-type and delta S-proteins, and binding analysis through competitive SPR assays using blood (co)-factors (antithrombin, heparin cofactor II and thrombin) and four S-proteins (wild-type, delta, gamma, and omicron) strongly support the conclusion about the deleterious impact of the AnGalp unit.
Identifiants
pubmed: 36963552
pii: S0141-8130(23)01062-0
doi: 10.1016/j.ijbiomac.2023.124168
pmc: PMC10175164
mid: NIHMS1888392
pii:
doi:
Substances chimiques
Galactans
0
Sulfates
0
Anticoagulants
0
Disaccharides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124168Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM130460
Pays : United States
Organisme : NINDS NIH HHS
ID : R03 NS110996
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interest. The funders had no role in the design, writing, or decision of this manuscript.
Références
Mar Drugs. 2015 May 15;13(5):2967-3028
pubmed: 25988519
Biochim Biophys Acta. 2012 Dec;1820(12):1971-9
pubmed: 22964140
Carbohydr Res. 2017 Sep 8;449:23-31
pubmed: 28683274
Cell Discov. 2020 Jul 24;6(1):50
pubmed: 32714563
Food Funct. 2020 Sep 23;11(9):7415-7420
pubmed: 32966484
Sci Rep. 2020 Nov 5;10(1):19076
pubmed: 33154514
Adv Food Nutr Res. 2012;65:195-209
pubmed: 22361188
Antiviral Res. 2021 Jun;190:105077
pubmed: 33864843
Carbohydr Polym. 2021 Nov 15;272:118526
pubmed: 34420760
Pharmaceuticals (Basel). 2015 Dec 10;8(4):848-64
pubmed: 26690451
Viruses. 2022 Feb 17;14(2):
pubmed: 35216006
Thromb Haemost. 2001 Dec;86(6):1540-6
pubmed: 11776325
Carbohydr Res. 2005 Oct 31;340(15):2392-402
pubmed: 16125685
Int J Biol Macromol. 2023 Feb 1;227:316-328
pubmed: 36481336
J Virol. 2021 Jan 13;95(3):
pubmed: 33173010
Pharmaceuticals (Basel). 2021 Jul 23;14(8):
pubmed: 34451811
J Am Chem Soc. 2020 Mar 18;142(11):5252-5265
pubmed: 32105452
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Mar Drugs. 2021 Jul 22;19(8):
pubmed: 34436245
Thromb Haemost. 2008 Mar;99(3):539-45
pubmed: 18327402
Adv Clin Chem. 2013;62:269-303
pubmed: 24772670
J Biol Chem. 2021 Oct;297(4):101207
pubmed: 34537241
J Biol Chem. 2000 Sep 22;275(38):29299-307
pubmed: 10882718
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
Thromb Haemost. 2008 Mar;99(3):531-8
pubmed: 18327401
J Biol Chem. 2022 May;298(5):101856
pubmed: 35337800
Eur J Biochem. 1987 Jul 15;166(2):431-6
pubmed: 3609020
J Chem Theory Comput. 2021 Jul 13;17(7):4291-4300
pubmed: 34096718
Glycoconj J. 2010 Jan;27(1):1-12
pubmed: 19568930
Int J Biol Macromol. 2020 May 3;158:471-476
pubmed: 32376249
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
Mar Drugs. 2015 May 06;13(5):2770-84
pubmed: 25955754
Carbohydr Res. 2012 Jan 10;347(1):114-20
pubmed: 22169178
Front Cell Infect Microbiol. 2014 Mar 06;4:33
pubmed: 24639954
Carbohydr Res. 2005 Sep 5;340(12):2015-23
pubmed: 16023626
Biopolymers. 2009 Aug;91(8):601-9
pubmed: 19353634
Glycobiology. 2023 Jan 8;33(1):75-85
pubmed: 36136750
Thromb Haemost. 2010 May;103(5):994-1004
pubmed: 20352164
Carbohydr Polym. 2022 Mar 15;280:119006
pubmed: 35027121
J Mol Biol. 2002 Jul 12;320(3):597-608
pubmed: 12096912
Glycobiology. 2022 Sep 19;32(10):849-854
pubmed: 35788318
Mar Drugs. 2012 Apr;10(4):793-811
pubmed: 22690144
Int J Biol Macromol. 2022 Feb 28;199:386-400
pubmed: 34973978
J Biol Chem. 2009 Jul 10;284(28):18790-800
pubmed: 19403528
J Thromb Haemost. 2014 Jan;12(1):43-53
pubmed: 24261511
Mar Drugs. 2021 Apr 15;19(4):
pubmed: 33921174
Carbohydr Res. 2021 Jul;505:108326
pubmed: 34015720
Nat Commun. 2022 Feb 15;13(1):871
pubmed: 35169135
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
J Med Chem. 2004 Mar 25;47(7):1750-9
pubmed: 15027866
Carbohydr Res. 1990 Dec 15;208:163-74
pubmed: 1964869
Proteins. 2004 May 1;55(2):351-67
pubmed: 15048827